Get the Stockscreener App
7.56
2.45%
-0.19
After Hours:
7.57
0.01
+0.13%
Neuraxis Inc stock is traded at $7.56, with a volume of 144.38K.
It is down -2.45% in the last 24 hours and up +25.17% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$7.75
Open:
$7.69
24h Volume:
144.38K
Relative Volume:
1.35
Market Cap:
$94.94M
Revenue:
$4.28M
Net Income/Loss:
$-7.28M
P/E Ratio:
-9.2806
EPS:
-0.8146
Net Cash Flow:
$-6.17M
1W Performance:
-0.66%
1M Performance:
+25.17%
6M Performance:
+0.67%
1Y Performance:
+174.91%
1-Day Range:
$7.56
$7.99
1-Week Range:
$6.94
$7.99
52-Week Range:
$2.21
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
7.56 | 94.94M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc Stock (NRXS) Latest News
Craig-Hallum Maintains Neuraxis(NRXS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com
NeurAxis secures major insurer coverage for IB-Stim device - Investing.com
NeurAxis secures major insurer coverage for IB-Stim device By Investing.com - Investing.com India
NeurAxis Announces Medical Coverage Policy Milestone, - GlobeNewswire
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives - Yahoo Finance
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference - Yahoo Finance
Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock? - tradingview.com
NeurAxis at iAccess Alpha conference: payer wins drive growth By Investing.com - Investing.com Nigeria
NRXS: Strong insurance coverage and clinical data position the company for rapid growth through 2027 - tradingview.com
NeurAxis at iAccess Alpha conference: payer wins drive growth - Investing.com
Is Kodak having a "Kodak moment?" 2 watchlist stocks. - tradingview.com
NRXS Forecast & Price Target - TradingKey
Neuraxis Inc. (NRXS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Neuraxis Inc. (NRXS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Neuraxis Inc. (NRXS) Peer Comparison – Compare with Others - Value Research
Neuraxis Inc. (NRXS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Neuraxis | 4: Statement of changes in beneficial ownership of securities-Officer Carrico Thomas Joeseph - Moomoo
Neuraxis (NRXS) Q2 2026 Earnings: EPS Beats Its Estimate in the Latest Session; Price Move: Shares Finish 1.91% Down in the Current UpdateEarnings Expansion Phase - vinanet.vn
NeurAxis Earnings Call Signals High Growth, High Hurdles - TipRanks
NeurAxis Enhances Executive and Director Equity Compensation - TipRanks
Neuraxis (NRXS) grants CEO 199K instantly vesting stock units - Stock Titan
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up - NewsBreak: Local News & Alerts
Neuraxis (NRXS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Jumps 32%Performance Review - vinanet.vn
NRXS Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 32% Stock SurgeEarnings Per Share - vinanet.vn
Neuraxis Inc. (NRXS) Q2 2026 Earnings: Narrower Loss Beats Expectations as Stock Holds SteadyStrong Earnings Momentum - vinanet.vn
NRXS Q2 2026 Earnings: EPS Surprises to the Upside as Net Loss NarrowsTax Rate Impact - careplusvn.com
NRXS Q2 2026 Earnings: 41.79% EPS Beat Signals Cost Discipline, Yet Shares Slip 1.26%Return On Assets - vinanet.vn
NeurAxis revenues up 116% to USD 1.9M in Q2 2026 - Medical Buyer
NeurAxis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
NeurAxis (NRXS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Could NeurAxis (NASDAQ:NRXS) Reshape Nasdaq Composite Focus? - Kalkine Media
Transcript : NeurAxis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
NeurAxis (NASDAQ:NRXS): What Could Today’s Update Reveal About Pediatric Therapy Adoption And Reimbursement? - Kalkine Media
NRXS: Q2 revenue up 116% YoY, gross margin at 85.9%, with payer coverage and VA expansion driving growth - TradingView
Earnings call transcript: NeurAxis falls on Q2 2026 EPS miss despite 116% revenue growth - Investing.com
NeurAxis reports 116% revenue growth in second quarter 2026 By Investing.com - Investing.com Nigeria
NeurAxis reports 116% revenue growth in second quarter 2026 - Investing.com
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth - The Manila Times
NRXS: Q2 2026 revenue surged 116% year-over-year, with gross margin up to 85.9% and strong cash position - TradingView
NRXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NeurAxis (NYSE American: NRXS) doubles sales yet warns on going concern - Stock Titan
Earnings To Watch: Neuraxis Inc (NRXS) Q2 2026 -- GF Value Sees 55% Downside - Yahoo Finance
NeurAxis, Inc. (NRXS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
NeurAxis宣佈爲IB-Stim PENFS療法增加美國中大西洋地區的覆蓋範圍，將服務擴展至超過500,000人 - Moomoo
Neuraxis Expands Payer Coverage for Percutaneous Electrical Nerve Field Stimulation and Ib-Stim Treatment - marketscreener.com
NeurAxis Expands Payer Coverage with New Policies - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Neuraxis Q1 2026 Earnings: Narrower-Than-Expected Loss as EPS Beats Consensus by 7.12%Guidance Revision Trend - dars.gov.et
NRXS|Neuraxis Inc|Price:6.735|Chg%:+0.485 - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuraxis Inc Stock (NRXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Cap:
|
Volume (24h):